191 related articles for article (PubMed ID: 37339179)
1. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.
Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA
Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179
[TBL] [Abstract][Full Text] [Related]
2. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
3. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
4. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH
Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
8. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG
Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304
[TBL] [Abstract][Full Text] [Related]
9. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
[TBL] [Abstract][Full Text] [Related]
10. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Prudner BC; Rathore R; Robinson AM; Godec A; Chang SF; Hawkins WG; Hirbe AC; Van Tine BA
Clin Cancer Res; 2019 Aug; 25(16):5122-5134. PubMed ID: 31113844
[TBL] [Abstract][Full Text] [Related]
11. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N
Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006
[TBL] [Abstract][Full Text] [Related]
13. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
[TBL] [Abstract][Full Text] [Related]
14. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
15. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
16. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
Bean GR; Kremer JC; Prudner BC; Schenone AD; Yao JC; Schultze MB; Chen DY; Tanas MR; Adkins DR; Bomalaski J; Rubin BP; Michel LS; Van Tine BA
Cell Death Dis; 2016 Oct; 7(10):e2406. PubMed ID: 27735949
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
Syed N; Langer J; Janczar K; Singh P; Lo Nigro C; Lattanzio L; Coley HM; Hatzimichael E; Bomalaski J; Szlosarek P; Awad M; O'Neil K; Roncaroli F; Crook T
Cell Death Dis; 2013 Jan; 4(1):e458. PubMed ID: 23328665
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.
Locke M; Ghazaly E; Freitas MO; Mitsinga M; Lattanzio L; Lo Nigro C; Nagano A; Wang J; Chelala C; Szlosarek P; Martin SA
Cell Rep; 2016 Aug; 16(6):1604-1613. PubMed ID: 27452468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
